93 355

Cited 13 times in

Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma

DC Field Value Language
dc.contributor.authorJung, HJ-
dc.contributor.authorChen, Z-
dc.contributor.authorMcCarty, N-
dc.date.accessioned2013-04-29-
dc.date.available2013-04-29-
dc.date.issued2012-
dc.identifier.issn0361-8609-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/8020-
dc.description.abstractMantle cell lymphoma (MCL) is a subtype of B-cell Non-Hodgkin's Lymphoma (NHL) and accounts for ~6% of all lymphomas. MCL is highly refractory to most chemotherapy including newer antibody-based therapeutic approaches, and high-grade MCL has one of the worst survival rates among NHLs. Therefore, the development of new therapeutic strategies to overcome drug resistance of MCL is important. In this article, we tested the effects of arsenic trioxide (As(2) O(3) , ATO) in bortezomib-resistant MCL. ATO is reported to induce complete remission in the patients with relapsed or refractory acute promyelocytic leukemia. Their effects in MCL, however, have not been explored. In this report, we show that ATO effectively inhibited the growth of MCL cells in vitro. ATO treatment also reduced cyclin D1 expression which is a genetic hallmark of MCL and NF-kB expression which was reported to have a prosurvival role in some MCL cells. The induction of apoptosis in MCL was partially due to reduced levels of cyclin D1 and increased levels of apoptosis-related molecules. The antiproliferative effects of bortezomib on MCL greatly increased when the cells were also treated with ATO, indicating ATO can sensitize MCL to bortezomib. Similar results were noted in bortezomib-resistant cell lines. In conclusion, ATO may be an alternative drug for use in combined adjuvant therapies for MCL, and further clinical testing should be performed.-
dc.language.isoen-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects/*pharmacology-
dc.subject.MESHApoptosis/drug effects-
dc.subject.MESHArsenicals/administration & dosage/adverse effects/*pharmacology-
dc.subject.MESHBoronic Acids/administration & dosage/adverse effects/*pharmacology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Proliferation/drug effects-
dc.subject.MESHCell Survival/drug effects-
dc.subject.MESHCyclin D1/biosynthesis-
dc.subject.MESHDrug Synergism-
dc.subject.MESHHumans-
dc.subject.MESHLymphoma, Mantle-Cell/*drug therapy/metabolism/pathology-
dc.subject.MESHOxides/administration & dosage/adverse effects/*pharmacology-
dc.subject.MESHPyrazines/administration & dosage/adverse effects/*pharmacology-
dc.titleSynergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma-
dc.typeArticle-
dc.identifier.pmid22965904-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894928/-
dc.contributor.affiliatedAuthor정, 현주-
dc.type.localJournal Papers-
dc.identifier.doi10.1002/ajh.23317-
dc.citation.titleAmerican journal of hematology-
dc.citation.volume87-
dc.citation.number12-
dc.citation.date2012-
dc.citation.startPage1057-
dc.citation.endPage1064-
dc.identifier.bibliographicCitationAmerican journal of hematology, 87(12):1057-1064, 2012-
dc.identifier.eissn1096-8652-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse